SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
Open Access
- 12 January 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (6), 817-819
- https://doi.org/10.1136/annrheumdis-2020-219808
Abstract
No abstract availableFunding Information
- Brigham Research Institute
- Rheumatology Research Foundation (R Bridge Award, Scientist Development Award)
- National Institutes of Health (K23-AR-069688, K23-AR-073334, L30-AR-066953, L30-AR-070520, P30-AR-070253, P30-AR-072577, R03-AR-075886, T32-AR-007258)
- R. Bruce and Joan M. Mickey Research Scholar Fund
This publication has 7 references indexed in Scilit:
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19The New England Journal of Medicine, 2021
- Dexamethasone in Hospitalized Patients with Covid-19The New England Journal of Medicine, 2021
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersThe New England Journal of Medicine, 2021
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostThe New England Journal of Medicine, 2020
- Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemicAnnals Of The Rheumatic Diseases, 2020
- Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19Cell, 2020